Form 4: Precigen Executive Phil Tennant Reports Stock Transactions Following PSU Vesting

Precigen's Chief Commercial Officer, Phil Tennant, acquired 25,000 shares of common stock upon vesting of performance stock units and sold 9,441 shares to cover tax obligations.

Summary

• Phil Tennant, Chief Commercial Officer of Precigen, Inc., reported a transaction involving the company's common stock.
• On January 29, 2025, Mr. Tennant acquired 25,000 shares of common stock as part of the settlement of performance stock units (PSUs).
• These PSUs were originally granted on August 28, 2024, and vested upon the achievement of certain performance conditions.
• Concurrently, 9,441 shares were sold at a price of $1.30 per share to cover income tax withholding obligations related to the PSU settlement.
• Following these transactions, Mr. Tennant's direct holdings of Precigen common stock decreased to 15,559 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs is a positive sign, but the subsequent sale of shares for tax purposes is a neutral event. There is no indication of any negative sentiment.

Positives

• The vesting of performance stock units indicates that performance goals were met, which is a positive sign for the company.
• The acquisition of 25,000 shares by a key executive demonstrates confidence in the company's future.

Negatives

• The sale of 9,441 shares, while for tax purposes, could be perceived negatively by some investors as a reduction in the executive's holdings.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.
• The market may interpret the sale of shares as a lack of confidence, despite the explanation provided.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into executive compensation and ownership.

Comparison to Industry Standards

• The vesting of performance stock units is a common practice in the biotechnology industry to incentivize executives.
• The sale of shares to cover tax obligations is also a standard practice.
• Similar filings are regularly made by executives at comparable companies such as Intellia Therapeutics, CRISPR Therapeutics, and Editas Medicine.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of company performance.
• The sale of shares by an executive, even for tax purposes, may cause some short-term concern among shareholders.

Key Dates

Keywords

Precigen, stock, performance stock units, PSU, Phil Tennant, executive, SEC Form 4, vesting, tax withholding, common stock